Do you refrigerate retatrutide? Storage isn't the real issue

Last updated 2026-07-25

Do you refrigerate retatrutide?

If you're asking this question, you probably already have a vial in hand, which is itself the issue worth pausing on. There is no FDA-approved retatrutide product, so there's no official prescribing information, no manufacturer-tested stability data, and no label telling you 2-8°C versus room temperature ^[1]. Anything you've read about "refrigerate after reconstitution" for retatrutide is borrowed, usually from tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy) labeling, or it's a guess from a gray-market seller with no obligation to get it right. Peptides in this general class (GLP-1, GIP, and glucagon receptor agonists) do tend to be temperature-sensitive proteins that degrade faster at room temperature and faster still if frozen or shaken hard. That's true of the approved drugs in this family. But "probably behaves similarly" is not the same as verified stability data, and nobody has published a controlled shelf-life study on retatrutide handling because it isn't sold as a finished, tested pharmaceutical product anywhere in the US ^{[1] [2]}. The honest answer: if you have unapproved research material, you're managing an unknown-stability compound with no quality control, not following a real drug's storage protocol. That's a different risk category than "should I keep my Ozempic pen in the fridge."

Why doesn't retatrutide have an official storage label?

Because it isn't an approved drug. A search of Drugs@FDA, the FDA's own database of approved products, returns no approved application for retatrutide under any brand or generic listing ^[1]. No approval means no FDA-reviewed label, and the label is where storage instructions (temperature range, light exposure, use-by period after reconstitution) legally come from. Compare that to orforglipron, an oral GLP-1 drug approved in 2026 as FOUNDAYO under NDA 220934 in strengths from 0.8 mg to 17.2 mg ^[3]. That approval came with a full label, including handling instructions, because FDA reviewed manufacturing and stability data as part of the application. Retatrutide has no equivalent because it has never cleared that bar. Everything circulating online about how to store it is inference, not regulation.

Is retatrutide legal to buy or possess in the US?

It's legal to study in a clinical trial. It is not legal to sell as a drug for human use, and it has no lawful compounding pathway either. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application, and retatrutide has none ^[4]. That statute is the entire reason it's unavailable outside registered trials. Some people assume a compounding pharmacy can just make it. That's not how 503A compounding works. Section 503A permits compounding from a bulk substance only through a strict cascade: the substance must comply with a USP or NF monograph if one exists, and if none exists it must be a component of an FDA-approved drug, and only if neither of those applies can it come from the FDA's 503A Bulks List ^[5]. Retatrutide fails all three tests. There's no monograph, no approved product it's a component of, and it isn't on the list. The list itself is short and specific. The complete final 503A Bulks List at 21 CFR 216.23 contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[2]. No peptide is on it. Retatrutide isn't on it. The separate 503B bulks list, which governs outsourcing facilities rather than 503A compounding pharmacies, is at 21 CFR 216.24 and also doesn't include it ^[6]. FDA's public roster of nominated bulk substances confirms the same thing: retatrutide simply isn't in any interim compounding category ^{[7] [8]}.

Could retatrutide get added to the compounding list soon?

Not on any visible timeline, and it hasn't even been formally proposed. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[9]. Retatrutide wasn't among them and, per the same Federal Register docket, has never been nominated for that list ^[9]. Even if it had been nominated and even if the committee voted favorably, that wouldn't create a legal pathway on its own. Advisory committee recommendations are non-binding, and actually adding a substance to the 503A Bulks List requires full notice-and-comment rulemaking, which takes years, not months ^[9]. So the realistic timeline for a legal compounding route, if one ever opens, is measured in years from today, assuming someone even nominates it.

Separate from the ingredient cascade, is there another legal barrier?

Yes, and it's independent of the monograph question. Section 503A also requires every bulk drug substance used in compounding to be manufactured by an establishment registered under section 510 of the FD&C Act and to come with a valid certificate of analysis ^[5]. Research-use-only material from unregistered overseas suppliers fails this requirement regardless of anything else, meaning even if retatrutide magically qualified under the ingredient cascade tomorrow, product from a typical peptide vendor still wouldn't meet the sourcing rule ^[5]. This is why "research use only" labeling on a vial doesn't fix the legal problem. It just means the seller is trying to dodge a different rule, the one about what counts as intended use.

Does a 'research use only' label make it legal to sell or use?

No. FDA has been explicit that a disclaimer doesn't override how a product is actually marketed. Intended use is judged by labeling claims, advertising, and statements by the seller, not by a footer disclaimer, under 21 CFR 201.128 ^[10]. FDA acted on exactly this in a March 2026 warning letter to Gram Peptides (MARCS-CMS 721806), writing that despite "research use only" and "not for human consumption" labeling, evidence from the company's website established that its products, including retatrutide, were intended to be drugs for human use ^[11]. The letter specifically named retatrutide as one of the products marketed that way. If a site describes weight loss effects, dosing suggestions, or therapeutic benefits, FDA treats that as drug marketing no matter what the label says. That's the legal reality behind every gray-market retatrutide vial: the seller's own marketing copy is usually what establishes the violation.

What did the actual retatrutide trials study, and how was it dosed?

Retatrutide is being studied as a once-weekly subcutaneous injection. In the phase 2 obesity trial (registered as NCT04881760, development code LY3437943), the 12 mg dose arm produced a mean weight reduction of 24.2 percent at 48 weeks, compared with 2.1 percent for placebo ^{[12] [13]}. That trial is published in the New England Journal of Medicine ^[12]. Mechanistically, retatrutide is a triple agonist, acting at the GIP, GLP-1, and glucagon receptors, which is what separates it from semaglutide (GLP-1 only) and tirzepatide (GIP and GLP-1 only) ^[12]. That triple mechanism is the scientific reason for interest in it, but it's also exactly why nothing about semaglutide or tirzepatide's approved storage instructions can be assumed to transfer cleanly. Different molecule, different degradation behavior, unverified in any public dataset. Retatrutide has since moved into later-phase registered trials (NCT05929066 and NCT05882045), whose public records list enrollment criteria, comparators, and endpoints, and it's also been studied in type 2 diabetes trials beyond the obesity program ^{[13] [14] [1]}. None of this trial activity changes its legal status today. It remains investigational, meaning it has not completed the FDA review process required for approval. See our dosage chart piece for how trial doses map across the studied range, and how to reconstitute retatrutide if you want the mechanics trial sites actually use, understanding that no clinician can lawfully prescribe it outside a trial.

If it degrades with heat, why do vendors say room temperature is fine?

Because it's cheaper and easier to ship, and because there's no regulator checking their claims against real stability data. A vendor selling unapproved research material has no FDA-reviewed testing behind any storage claim it makes. That's a fundamentally different situation from an approved drug, where the manufacturer had to submit stability studies to FDA as part of getting the label approved. So when a listing says "stable at room temperature for 30 days," ask yourself: stable according to what test, verified by whom, published where? For approved GLP-1 drugs, that data exists and is public. For retatrutide, it doesn't exist in any form you can check, because the compound has never gone through the approval process that would produce it ^[1].

What are the actual safety risks of using unregulated retatrutide?

You're combining three separate unknowns: purity, potency, and degradation, on top of a drug whose safety profile in the general population still isn't fully characterized even in its trial form. Material from unregistered manufacturers comes with no enforceable certificate of analysis requirement ^[5], so you can't verify what's actually in the vial or at what concentration. The published trial data on retatrutide comes from controlled studies with defined dosing, monitoring, and eligibility criteria ^{[12] [13]}. Self-directed use of research chemicals mimics none of that. There's no clinician checking labs, no standardized dose escalation, and no verified sterility. For a fuller rundown of adverse effects reported in trials, see our retatrutide side effects page, but understand that trial safety data describes controlled administration, not what happens with unverified vials and guesswork storage.

What are the legal alternatives right now?

If you want an incretin therapy today, the lawful options are the approved ones. Semaglutide is marketed as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound, both with FDA-reviewed labels, published safety data, and real prescribing guidelines ^[15]. Orforglipron, an oral option, was approved as FOUNDAYO under NDA 220934 in 2026 ^[3]. All three came through the FDA review and approval process retatrutide hasn't completed. That means a real label, real storage instructions, a real supply chain, and a doctor who can actually monitor you. NIDDK publishes federal guidance on evidence-based weight management strategies that's a useful neutral starting point if you're comparing options with a clinician ^[16]. Retatrutide Report exists to track the trial evidence as it develops, not to help anyone work around the law, so if you're weighing whether to wait for a possible future approval versus starting an approved therapy now, that's a conversation for a prescriber, not a vendor's FAQ page.

What happens if retatrutide gets FDA approved eventually?

If and when that happens, the storage question answers itself: FDA review of the New Drug Application would require the manufacturer to submit real stability data, and the approved label would state an exact temperature range, light sensitivity information, and an in-use shelf life after reconstitution, the same way Ozempic, Wegovy, Mounjaro, and Zepbound labels do today. Until that happens, retatrutide sits in the same bucket every unapproved investigational drug sits in: promising phase 2 and phase 3 data ^{[12] [13] [14]}, zero approved product, and zero legal path to a pharmacy shelf. That's not a storage question. That's a regulatory status question, and right now the answer is unambiguous.

Frequently asked questions

Do you refrigerate retatrutide after reconstitution?

There's no approved drug label to answer this because retatrutide hasn't cleared FDA review ^[1]. Anything circulating about refrigeration mirrors approved GLP-1 drug labels like tirzepatide's, not verified retatrutide data. No controlled stability study on retatrutide handling has been published, so any storage claim from a vendor is unverified.

Can a pharmacy legally compound retatrutide?

No. Section 503A requires a bulk substance to meet a monograph, be a component of an approved drug, or appear on the 503A Bulks List ^[3]. Retatrutide meets none of these, and the final list at 21 CFR 216.23 contains only six substances, none a peptide ^[2]. Compounding it violates the statute.

Is retatrutide on the FDA's 503A Bulks List?

No. The complete final 503A Bulks List has exactly six entries: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[2]. Retatrutide isn't among them, and FDA's public nominations tracker confirms it sits in no interim compounding category either ^[13][17].

Does 'research use only' labeling make retatrutide legal to sell?

No. FDA judges intended use by marketing claims and advertising, not disclaimers, under 21 CFR 201.128 ^[7]. A March 2026 warning letter to Gram Peptides found that despite RUO labeling, the company's website marketed retatrutide as a drug for human use, which is a labeling violation regardless of the disclaimer ^[5].

What weight loss did retatrutide show in trials?

In the phase 2 obesity trial, the 12 mg weekly dose produced a mean 24.2 percent weight reduction at 48 weeks versus 2.1 percent for placebo ^[6]. That trial, registered as NCT04881760 under development code LY3437943, is published in the New England Journal of Medicine and used weekly subcutaneous injection ^[6][11].

Is retatrutide the same as tirzepatide or semaglutide?

No. Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors. Semaglutide (Ozempic, Wegovy) acts only on GLP-1, and tirzepatide (Mounjaro, Zepbound) acts on GIP and GLP-1 ^[6][16]. The different mechanism means storage and safety data can't be assumed to transfer between them.

Can I legally import retatrutide from overseas for personal use?

FDA's personal importation policy governs this, and unapproved drugs generally don't qualify for the narrow exceptions that policy allows ^[19]. Combined with the section 355 requirement that new drugs need an approved application to enter interstate commerce ^[8], personal importation of retatrutide sits outside lawful channels.

Will retatrutide ever be added to the compounding list?

It hasn't even been nominated. FDA's July 2026 advisory committee considered seven other peptides for the 503A list; retatrutide wasn't one of them ^[9]. Even a favorable vote wouldn't create a pathway automatically, since advisory recommendations are non-binding and adding a substance requires full notice-and-comment rulemaking ^[9].

What's a legal alternative to retatrutide right now?

Approved incretin drugs: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newer oral option orforglipron, approved as FOUNDAYO under NDA 220934 ^[10][16]. All come with FDA-reviewed labels, verified storage instructions, and clinician oversight, none of which exists for retatrutide.

Why doesn't retatrutide have an official prescribing label?

Because FDA has not approved it for any indication. A Drugs@FDA search for retatrutide returns no approved product ^[1]. Without approval there's no FDA-reviewed label, and storage instructions, dosing, and stability data legally originate from that label, which retatrutide simply doesn't have.

Is buying retatrutide from a peptide vendor a criminal risk?

Selling an unapproved new drug for human use without FDA approval violates 21 U.S.C. 355 ^[8], and FDA has issued warning letters over exactly this kind of marketing ^[5]. Enforcement typically targets sellers, but buyers also face real safety exposure from unverified purity, potency, and sourcing with no certificate of analysis requirement met ^[4].

How is retatrutide being studied beyond obesity?

Retatrutide has registered trials in type 2 diabetes in addition to the obesity program under NCT04881760, and has advanced into later-phase trials registered as NCT05929066 and NCT05882045, which list enrollment criteria, comparators, and endpoints publicly ^[11][12][15].

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for retatrutide returns no FDA-approved product for any indication
2. 21 CFR 216.23, eCFR: The complete final 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them
3. 21 U.S.C. 353a(b)(1)(A)(i): 503A compounding requires the ingredient cascade of monograph, then approved-drug component, then Bulks List, which retatrutide meets none of
4. Jastreboff AM et al., New England Journal of Medicine, 2023: Retatrutide 12 mg produced 24.2 percent mean weight reduction at 48 weeks versus 2.1 percent placebo; retatrutide is a triple GIP/GLP-1/glucagon receptor agonist
5. 21 CFR 201.128: Intended use is established by labeling claims, advertising, and seller statements, not disclaimers
6. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an approved application
7. Federal Register, Docket FDA-2025-N-6895: FDA's July 2026 advisory committee considered seven other peptides for the 503A list, not retatrutide, and advisory votes are non-binding requiring rulemaking to change the list
8. Drugs@FDA, NDA 220934: Orforglipron was approved as FOUNDAYO under NDA 220934 in six strengths from 0.8 mg to 17.2 mg
9. ClinicalTrials.gov NCT04881760: The phase 2 retatrutide obesity trial is registered under development code LY3437943 with dose arms and route specified
10. ClinicalTrials.gov NCT05929066: Retatrutide has advanced into a later-phase registered trial with listed enrollment criteria, comparators, and endpoints
11. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public list of nominated bulk substances for 503A compounding does not include retatrutide
12. 21 CFR 216.24: The separate 503B bulks list for outsourcing facilities also does not include retatrutide
13. ClinicalTrials.gov NCT05882045: A second later-phase retatrutide trial registration provides an independent record of dosing and design under study
14. FDA, Bulk Drug Substances Nominated for Use in Compounding (PDF): FDA's nominations document lists interim compounding categories and does not place retatrutide in any of them
15. NIDDK, Weight Management: NIDDK publishes federal guidance on evidence-based weight management as a neutral reference point
16. FDA, Personal Importation: FDA's personal importation policy governs attempts to bring unapproved drugs into the US for personal use